Recommended

FDA tightens COVID vaccine use
Decentralised manufacturing consortium launched
Trial boost for myasthenia gravis drug
FDA starts publishing daily AE data
WEBINAR | The Future of Sterility Testing: One-Day Results with Advanced RT-rt PCR Technology | 5 NOV
WEBINAR | Mastering Impurity Profiling: USP’s Evolving Standards and Strategies | 15 OCT
news

Treating malaria using artemisinin-based combination therapy (ACT)

20
SHARES

The artemisinin-based combination therapy (ACT), pyronaridine-artesunate, has been shown to be as effective in treating malaria as other drugs…

ACT

A study has given insight on the efficacy of using artemisinin-based combination therapy (ACT), pyronaridine-artesunate, for the treatment of malaria in areas of the world where resistance to other ACTs is now becoming a problem.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

The researchers found this treatment to be as effective as the currently used treatment, and in some cases was better. Researchers at the Liverpool School of Tropical Medicine, looked at results from ten clinical trials that made a comparison between pyronaridine-artesunate and other currently used treatments for people affected by Plasmodium falciparum malaria. 

The World Health Organization (WHO) currently recommends that ACTs are used to treat uncomplicated P. falciparum malaria. However, due to their ongoing artemisinin resistance, global initiatives have been launched to develop new and partner drugs to protect the efficacy of the original treatment.

The independant authors, Joseph Pryce and Dr Paul Hine assessed the efficacy of pyronaridine-artesunate for the treatment of malaria.

The corresponding author of the study, Dr Hine, said: “The need to find novel ACTs is important so that we can protect the efficacy of the artemisinin derivatives within them. The evidence that we found clearly showed at pyronaridine-artesunate performs as well, if not better than some of the currently marketed ACTs.”

Of the ten studies investigated, five of them specifically looked at the safety of the drug, with two of the trials exclusively recruiting children under the age of 12.

Pryce, one of the authors, said: “We found that pyronaridine-artesunate did increase the risk of having blood tests that showed mild liver injury, but there was no evidence that this caused severe or irreversible damage.

“The findings of this review’s efficacy analysis support the recommendation for using pyronaridine-artesunate in areas of multiple drug resistance, providing effective malaria treatment where other treatments may be failing.”

The full study can be found here.

Share via
Share via